Wenjie Chen
Guangzhou, 510630, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Erratum: Theranostical nanosystem-mediated identification of an oncogene and highly effective therapy in hepatocellular carcinoma.
Journal: Hepatology (Baltimore, Md.)
Published: March 27, 2025
Radiotherapy plus a self-gelation powder encapsulating tRF5-GlyGCC inhibitor potentiates natural kill cell immunity to prevent hepatocellular carcinoma recurrence.
Journal: Journal of nanobiotechnology
Published: November 27, 2024
A spreadable self-gelling hemostatic powder sensitizes CAR-NK cell therapy to prevent hepatocellular carcinoma recurrence postresection.
Journal: Journal of nanobiotechnology
Published: October 27, 2024
METTL3 knockout accelerates hepatocarcinogenesis via inhibiting endoplasmic reticulum stress response.
Journal: FEBS open bio
Published: September 21, 2024
A self-gelling hemostatic powder boosting radiotherapy-elicited NK cell immunity to combat postoperative hepatocellular carcinoma relapse.
Journal: Biomaterials
Published: August 11, 2024
Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma post-liver transplantation: results from a phase I trial.
Journal: Hepatology international
Published: December 04, 2022
MUTYH is a potential prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma.
Journal: Liver research (Beijing, China)
Published: October 22, 2022
Theranostical nanosystem-mediated identification of an oncogene and highly effective therapy in hepatocellular carcinoma.
Journal: Hepatology (Baltimore, Md.)
Published: May 19, 2015
Showing 1-10 of 10
Last Updated: 09/26/2026